Table 2.
Demographic and Clinical Characteristics From 20 Subjects With Acute Hepatitis C Virus (HCV) Monoinfection at Screening
| Subject (Study ID) | Age, y | Sex | Genotype | Duration of HCV infection, wk | HCV Clinical Symptomsa | Risk Factor | HCV RNA, log10 IU/mL | ALT, IU/L | HCV Virological Study Outcomeb |
|---|---|---|---|---|---|---|---|---|---|
| Monoinfection | |||||||||
| Mo1 (104) | 30 | Female | 2a/c | 12 | Yes (2) | Sexual | 3.04 | 223 | Persist |
| Mo2 (106) | 25 | Male | 3a | 7 | No | IDU | 5.03c | 1235c | Clear |
| Mo3 (109) | 34 | Male | 1a | 14 | No | IDU | 4.76 | 281c | NR |
| Mo4 (110) | 17 | Male | 2 | 9 | Yes (3) | IDU | 4.68 | 468c | NR |
| Mo5 (118) | 42 | Male | 1a | 15 | Yes (3, 4) | Sexual | 6.05c | 355c | SVR |
| Mo6 (201) | 48 | Male | 3a | 17 | No | IDU | 6.40 | 155c | Persist |
| Mo7 (202) | 43 | Male | 3a | 18 | No | IDU | 4.40c | 45c | SVR |
| Mo8 (205) | 38 | Male | 1a/3a | 24 | No | IDU | 4.55 | 129 | SVR |
| Mo9 (302) | 47 | Male | 1 | 21 | No | Other | 3.59c | 59 | SVR |
| Mo10 (307) | 28 | Female | 1a/b | 11 | No | IDU | 3.46 | 39 | Clear |
| Mo11 (308) | 25 | Male | 1 | 14 | Yes (1–3) | IDU | 1.00–2.97c | 104c | Clear |
| Mo12 (502) | 51 | Male | 1b | 19 | Yes (1–3) | IDU | 5.80 | 353c | SVR |
| Mo13 (604) | 36 | Male | 3a | 7 | Yes (1–5) | IDU | 6.02c | 1302c | SVR |
| Mo14 (606) | 18 | Female | 3a | 22 | Yes (2, 4) | IDU | 5.84 | 273 | NR |
| Mo15 (610) | 45 | Male | 1a | 25 | Yes (1–3) | IDU | 1.00–2.97c | 29 | SVR |
| Mo16 (614) | 24 | Female | 3a | 24 | No | IDU | 4.04 | 139 | Persist |
| Mo17 (639) | 24 | Female | 3a | 24 | Yes (2–4) | IDU | 3.31 | 33 | SVR |
| Mo18 (806) | 23 | Male | 1b | 17 | No | IDU | 5.01 | 486c | SVR |
| Mo19 (1101) | 28 | Male | 3a | 25 | No | IDU | 4.89c | 135c | Reinfect |
| Mo20 (1603) | 35 | Female | 3a | 19 | Yes (1, 2) | IDU | 3.77 | 174 | NR |
Abbreviations: ALT, alanine aminotransferase; ID, identification number; IDU, injection drug use; NR, nonresponder; SVR, sustained virological responder.
a Specific clinical symptoms are indicated numerically: 1, jaundice; 2, nausea; 3, abdominal pain; 4, fever; 5, hepatomegaly.
b Outcomes were defined as follows: clear, untreated subject with HCV clearance; NR, treated subject with viral persistence; persist, untreated subject with viral persistence; reinfect, subject who was reinfected; SVR, treated subject with HCV clearance who remained HCV negative; unknown, subject lost to follow-up before a study outcome was established.
c Peak RNA and ALT levels.